Top

EJNMMI Research

Published in:

Open Access 01-12-2015 | Original research

Longitudinal tumor hypoxia imaging with [¹⁸F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity

Authors: Jinzi Zheng, Stephan G. Klinz, Raquel De Souza, Jonathan Fitzgerald, David A. Jaffray

Published in: EJNMMI Research | Issue 1/2015

Abstract

Background

Non-invasive measurement of tumor hypoxia has demonstrated potential for the evaluation of disease progression, as well as prediction and assessment of treatment outcome. [¹⁸F]fluoroazomycin arabinoside (FAZA) positron emission tomography (PET) has been identified as a robust method for quantification of hypoxia both preclinically and clinically. The goal of this investigation was to evaluate the feasibility and value of repeated FAZA-PET imaging to quantify hypoxia in tumors that received multi-dose chemotherapy.

Methods

FAZA-PET imaging was conducted over a 21-day period in a mouse xenograft model of HT-29 human colorectal carcinoma, following multi-dose chemotherapy treatment with irinotecan (CPT-11) or nanoliposomal irinotecan (nal-IRI, MM-398).

Results

Tumors treated with 10 mg/kg nal-IRI maintained significantly lower levels of hypoxia and smaller hypoxic fractions compared to tumors that received 50 mg/kg CPT-11. Specifically, differences in FAZA uptake were detectable 9 days before any significant differences in tumor volume were observed between the treatment groups.

Conclusions

These findings highlight the potential use of FAZA-PET as an early marker of treatment response following multi-dose chemotherapy.

Available only for authorised users

Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–54. doi:10.1093/jnci/djm135.CrossRefPubMed

Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol. 2011;101:369–75. doi:10.1016/j.radonc.2011.07.029.PubMedCentralCrossRefPubMed

Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18 F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008;70:1219–28. doi:10.1016/j.ijrobp.2007.09.050.PubMedCentralCrossRefPubMed

Beck R, Roper B, Carlsen JM, Huisman MC, Lebschi JA, Andratschke N, et al. Pretreatment 18 F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med. 2007;48:973–80. doi:10.2967/jnumed.106.038570.CrossRefPubMed

Busk M, Horsman MR, Jakobsen S, Keiding S, van der Kogel AJ, Bussink J, et al. Imaging hypoxia in xenografted and murine tumors with 18 F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008;70:1202–12. doi:10.1016/j.ijrobp.2007.11.034.CrossRefPubMed

Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2012;40:186–97. doi:10.1007/s00259-012-2258-x.CrossRefPubMed

Halmos GB, de Bruin LB, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18 F-fluoroazomycin-arabinoside (18 F-FAZA)-PET: a review. Clin Nucl Med. 2014;39:44-8. doi:10.1097/RLU.0000000000000286.CrossRefPubMed

Mortensen LS, Busk M, Nordsmark M, Jakobsen S, Theil J, Overgaard J, et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: a preclinical study. Radiother Oncol. 2011;99:418–23. doi:10.1016/j.radonc.2011.06.034.CrossRefPubMed

Schuetz M, Schmid MP, Potter R, Kommata S, Georg D, Lukic D, et al. Evaluating repetitive 18 F-fluoroazomycin-arabinoside (18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol. 2010;49:941–7. doi:10.3109/0284186X.2010.510145.CrossRefPubMed

10.

Guerin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, et al. In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis. Mol Med. 2012;18:83–94. doi:10.2119/molmed.2011.00120.PubMedCentralCrossRefPubMed

11.

Chapman DW, Jans HS, Ma I, Mercer JR, Wiebe LI, Wuest M, et al. Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy. EJNMMI Res. 2015;4:27. doi:10.1186/s13550-014-0027-5.CrossRef

12.

Ballegeer EA, Madrill NJ, Berger KL, Agnew DW, McNiel EA. Evaluation of hypoxia in a feline model of head and neck cancer using (64)Cu-ATSM positron emission tomography/computed tomography. BMC Cancer. 2013;13:218. doi:10.1186/1471-2407-13-218.PubMedCentralCrossRefPubMed

13.

Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;21:4893–902. doi:10.1039/b705989b.CrossRef

14.

Zhang T, Das SK, Fels DR, Hansen KS, Wong TZ, Dewhirst MW, et al. PET with (62)Cu-ATSM and (62)Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. AJR Am J Roentgenol. 2013;201:W698–706. doi:10.2214/AJR.12.9698.PubMedCentralCrossRefPubMed

15.

Zegers CM, van Elmpt W, Szardenings K, Kolb H, Waxman A, Subramaniam RM, et al. Repeatability of hypoxia PET imaging using [F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. Eur J Nucl Med Mol Imaging. 2015;42:1840-9. doi:10.1007/s00259-015-3100-z.PubMedCentralCrossRefPubMed

16.

Klaassen R, Bennink RJ, van Tienhoven G, Bijlsma MF, Besselink MG, van Berge Henegouwen MI, et al. Feasibility and repeatability of PET with the hypoxia tracer [F]HX4 in oesophageal and pancreatic cancer. Radiother Oncol. 2015;116:94-9. doi:10.1016/j.radonc.2015.05.009.CrossRefPubMed

17.

Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91:351–9. doi:10.1016/j.ijrobp.2014.09.045.CrossRefPubMed

18.

Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108:14620–5. doi:10.1073/pnas.1102526108.PubMedCentralCrossRefPubMed

19.

Peeters SG, Zegers CM, Biemans R, Lieuwes NG, van Stiphout RG, Yaromina A, et al. TH-302 in combination with radiotherapy enhances the therapeutic outcome and is associated with pretreatment [18F]HX4 hypoxia PET imaging. Clin Cancer Res. 2015;21:2984–92. doi:10.1158/1078-0432.CCR-15-0018.CrossRefPubMed

20.

Reischl G, Dorow DS, Cullinane C, Katsifis A, Roselt P, Binns D, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F] FAZA—first small animal PET results. J Pharm Pharm Sci. 2007;10:203–11.

21.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, et al. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. J Nucl Med. 2013;54:1106–12. doi:10.2967/jnumed.112.111120.CrossRefPubMed

22.

Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714–21. doi:10.1200/JCO.2006.10.5825.

23.

Mudd SR, Holich KD, Voorbach MJ, Cole TB, Reuter DR, Tapang P, et al. Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol Imaging Biol. 2012;14:617–24. doi:10.1007/s11307-011-0529-8.CrossRefPubMed

24.

Kalra AV, Kim J, Klinz SG, Paz N, Cain J, Drummond DC, et al. Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion. Cancer Res. 2014;74(23):7003-13. PMID: 25273092.CrossRefPubMed

25.

Kang MH, Wang J, Makena MR, Lee JS, Paz N, Hall CP, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21:1139–50. doi:10.1158/1078-0432.CCR-14-1882.CrossRefPubMed

26.

Von Hoff D, Li C, Wang-Gillam A, Bodoky G, Dean A, Jameson G, et al. NAPOLI-1: randomized phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer progressed on or following gemcitabine-based therapy. Ann Oncol. 2014;25:ii105–ii17.CrossRef

27.

Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–76. doi:10.1158/1078-0432.CCR-11-3114.PubMedCentralCrossRefPubMed

28.

Baker JH, Lam J, Kyle AH, Sy J, Oliver T, Co SJ, et al. Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res. 2008;14:7260–71. doi:10.1158/1078-0432.CCR-08-0736.CrossRefPubMed

29.

Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19:619–25. doi:10.1038/nm.3175.PubMedCentralCrossRefPubMed

30.

Busk M, Munk OL, Jakobsen S, Wang T, Skals M, Steiniche T, et al. Assessing hypoxia in animal tumor models based on pharmocokinetic analysis of dynamic FAZA PET. Acta Oncol. 2010;49:922–33. doi:10.3109/0284186X.2010.503970.CrossRefPubMed

31.

Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14–20. doi:10.1016/j.radonc.2012.09.015.CrossRefPubMed

32.

Vines D, McKee T, Mahmood J, Keller H, Jaffray D. Reproducibility of 18F-FAZA PET-CT mouse imaging. J Nucl Med. 2013;54:2534.

33.

Pommier Y. Topoisomerase I, inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802. doi:10.1038/nrc1977.CrossRefPubMed

34.

Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR, Jain RK. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res. 2013;73:3833–41. doi:10.1158/0008-5472.CAN-12-4521.PubMedCentralCrossRefPubMed

35.

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, et al. Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts. Neuro Oncol. 2012;15:189–97. doi:10.1093/neuonc/nos305.PubMedCentralCrossRefPubMed

36.

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013;24:1567–73. doi:10.1093/annonc/mdt002.CrossRefPubMed

Title: Longitudinal tumor hypoxia imaging with [18F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity
Authors: Jinzi Zheng
Stephan G. Klinz
Raquel De Souza
Jonathan Fitzgerald
David A. Jaffray
Publication date: 01-12-2015
Publisher: Springer Berlin Heidelberg
Published in: EJNMMI Research / Issue 1/2015
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-015-0135-x

At a glance: The STEP trials

Springer Medicine

Longitudinal tumor hypoxia imaging with [¹⁸F]FAZA-PET provides early prediction of nanoliposomal irinotecan (nal-IRI) treatment activity

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Effect of postconditioning on dynamic expression of tenascin-C and left ventricular remodeling after myocardial ischemia and reperfusion

Molecular imaging of angiogenesis after myocardial infarction by 111In-DTPA-cNGR and 99mTc-sestamibi dual-isotope myocardial SPECT

Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model

Radioiodinated PARP1 tracers for glioblastoma imaging

Evaluation of the delivered activity of yttrium-90 resin microspheres using sterile water and 5 % glucose during administration

Rapid kit-based 68Ga-labelling and PET imaging with THP-Tyr3-octreotate: a preliminary comparison with DOTA-Tyr3-octreotate